Clinical Trial: Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis
Study Status: Not yet recruiting
Recruit Status: Not yet recruiting
Study Type: Interventional
Official Title: Open-label Safety Study of Suprachoroidal Triamcinolone Acetonide Injectable Suspension in Patients With Non-Infectious Uveitis
Brief Summary: Open-label safety study of suprachoroidal triamcinolone acetone injectable suspension in patients with non-infectious uveitis.
Detailed Summary: This is a Phase 3, open-label, multi-center study to assess the safety of 4 mg of CLS-TA administered via suprachoroidal injection for the treatment of subjects with non-infectious uveitis.
Sponsor: Clearside Biomedical, Inc.
Current Primary Outcome: Adverse Events [ Time Frame: 24 weeks ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Clearside Biomedical, Inc.
Dates:
Date Received: March 27, 2017
Date Started: April 1, 2017
Date Completion: June 2018
Last Updated: March 27, 2017
Last Verified: March 2017